Sugi Predict

Sugi Predict / Compounds / SCHEMBL16082152

SCHEMBL16082152

SCHEMBL16082152

CC(C)(C)OC(=O)NCC(=O)NNC(=O)C(F)(F)F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ APLNR P35414 1/20 0.44
▸ CA14 Q9ULX7 2/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ MAOA P21397 1/20 0.39
▸ MAOB P27338 1/20 0.39
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ GAA P10253 2/20 0.38
▸ CTSK P43235 2/20 0.36
▸ ALDH1A1 P00352 2/20 0.35
▸ TSHR P16473 1/20 0.35
▸ POLB P06746 2/20 0.35
▸ LMNA P02545 1/20 0.35
▸ CA12 O43570 3/20 0.34
▸ CA2 P00918 3/20 0.34
▸ CA1 P00915 2/20 0.34
▸ CA9 Q16790 2/20 0.34
▸ EPHX1 P07099 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14721455 0.86 APLNR (0.42) APLNRCA14TDP1MAOAMAOB
SCHEMBL23568271 0.82 CA14 (0.49) APLNRCA14TDP1MAOAMAOB
SCHEMBL10071535 0.81 APLNR (0.44) APLNRCA14TDP1MAOAMAOB
SCHEMBL25063331 0.81 APLNR (0.44) APLNRCA14TDP1MAOAMAOB
SCHEMBL31347366 0.80 APLNR (0.49) APLNRCA14TDP1MEN1KMT2A
SCHEMBL14879230 0.79 TDP1 (0.44) APLNRCA14TDP1MAOAMAOB
SCHEMBL1934718 0.78 PTPN11 (0.43) APLNRCA14TDP1MAOAMAOB
SCHEMBL1289840 0.76 TDP1 (0.42) APLNRCA14TDP1MAOAMAOB
SCHEMBL23465643 0.76 TDP1 (0.42) APLNRCA14TDP1MAOAMAOB
SCHEMBL10309172 0.76 CA14 (0.45) APLNRCA14TDP1MAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3998260-B1 SGC STIMULATORS CYCLERION THERAPEUTICS INC (US) 2023-11-01 — — EP disclosed
EP-3998260-B1 SGC STIMULATORS CYCLERION THERAPEUTICS INC (US) 2023-11-01 — — EP disclosed
WO-2023192989-A2 PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS AZKARRA THERAPEUTICS, INC. (US) 2023-10-05 — — WO disclosed
WO-2023192989-A2 PHTHALAZINONE COMPOUNDS AS PARP7 INHIBITORS AZKARRA THERAPEUTICS, INC. (US) 2023-10-05 — — WO disclosed
US-20230106002-A1 sGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. 2023-04-06 — — US disclosed
CN-110016020-B Compound or pharmaceutically acceptable salt thereof, application and pharmaceutical composition thereof 赛克里翁治疗有限公司 2022-07-26 — — CN disclosed
EP-3998260-A1 SGC STIMULATORS Cyclerion Therapeutics, Inc. (US) 2022-05-18 — — EP disclosed
EP-3998260-A1 SGC STIMULATORS Cyclerion Therapeutics, Inc. (US) 2022-05-18 — — EP disclosed
EP-3660013-B1 SGC STIMULATORS CYCLERION THERAPEUTICS INC (US) 2022-01-19 — — EP disclosed
US-11207323-B2 sGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2021-12-28 — — US disclosed
US-10639308-B2 sGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2020-05-05 — — US disclosed
US-20190167679-A1 sGC STIMULATORS CYCLERION THERAPEUTICS, INC. 2019-06-06 — — US disclosed
US-10183021-B2 sGC stimulators IRONWOOD PHARMACEUTICALS, INC. (US) 2019-01-22 — — US disclosed
US-20170137439-A1 sGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2017-05-18 — — US disclosed
US-20170136019-A1 sGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2017-05-18 — — US disclosed
US-9586937-B2 sGC stimulators IRONWOOD PHARMACEUTICALS, INC. (US) 2017-03-07 — — US disclosed
US-20160347738-A1 sGC STIMULATORS CYCLERION THERAPEUTICS, INC. 2016-12-01 — — US disclosed
US-9481689-B2 sGC stimulators IRONWOOD PHARMACEUTICALS, INC. (US) 2016-11-01 — — US disclosed
US-20160031903-A1 sGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2016-02-04 — — US disclosed
WO-2014144100-A2 SGC STIMULATORS NAKAI TAKASHI (US) 2014-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230106002-A1 sGC STIMULATORS PTGIS, CGAS, GUCY1A1 APLNR 2621/4885CA14 4456/4885TDP1 711/4885
US-20170137439-A1 sGC STIMULATORS PTGIS, CGAS, GUCY1A1 APLNR 2621/4885CA14 4456/4885TDP1 711/4885
US-11207323-B2 sGC stimulators PTGIS, CGAS, GUCY1A1 APLNR 2621/4885CA14 4456/4885TDP1 711/4885
US-10639308-B2 sGC stimulators PTGIS, CGAS, GUCY1A1 APLNR 2621/4885CA14 4456/4885TDP1 711/4885
US-20160347738-A1 sGC STIMULATORS PTGIS, CGAS, GUCY1A1 APLNR 2621/4885CA14 4456/4885TDP1 711/4885
US-10183021-B2 sGC stimulators PTGIS, CGAS, GUCY1A1 APLNR 2621/4885CA14 4456/4885TDP1 711/4885
US-20170136019-A1 sGC STIMULATORS PTGIS, CGAS, GUCY1A1 APLNR 2621/4885CA14 4456/4885TDP1 711/4885
US-20190167679-A1 sGC STIMULATORS PTGIS, CGAS, GUCY1A1 APLNR 2621/4885CA14 4456/4885TDP1 711/4885
US-20160031903-A1 sGC STIMULATORS PTGIS, CGAS, GUCY1A1 APLNR 2621/4885CA14 4456/4885TDP1 711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.